Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara®)

British Journal of Dermatology

Volumn 150, Issue 6, 2004, Pages 1198-1201

  Didona, B ^a   Benucci, R ^a   Amerio, P ^a   Canzona, F ^a   Rienzo, O ^a   Cavalieri, R ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

Cytokines; Immune response modifiers; Primary cutaneous lymphoma; Treatment

Indexed keywords

CD20 ANTIBODY; CD3 ANTIGEN; CD30 ANTIGEN; CD45 ANTIGEN; IMIQUIMOD;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS T CELL LYMPHOMA; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; LYMPHOID CELL; MALE; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; SKIN BIOPSY; SKIN MANIFESTATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; AMINOQUINOLINES; ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; CYTOKINES; FOLLOW-UP STUDIES; HUMANS; INTERFERON TYPE II; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; SKIN NEOPLASMS;

EID: 3142655707     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.05993.x     Document Type: Article

References (16)

1. Bekkenk MW, Geelen FA, van Voorst Vader PC. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653-61.
2. Grange F, Bagot M. Prognosis of primary cutaneous lymphomas. Ann Dermatol Venereol 2002; 129: 30-40.
3. Hengge UR, Benninghoff B, Ruzika T et al. Topical immunomodulators - progress towards treating inflammation, infection, and cancer. Lancet Infect Dis 2001; 1: 189-98.
4. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000; 43: S6-11.
5. Beutner KR, Spruance SL, Hougham AL et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998; 38: 230-9.
6. Marks R, Gebauer K, Shumack S et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807-13.
7. Hengge UR, Starck R. Topical imiquimod to treat intraepidermal carcinoma. Arch Dermatol 2001; 137: 709-11.
8. Steinmann A, Funk JO, Schuler G, von den Driesch P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000; 43: 555-6.
9. Stockfleth E, Meyer T, Benninghoff B, Christophers E. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br J Dermatol 2001; 144: 1050-1.
10. Suchin KR, Junkins-Hopkins JM, Rook AH. Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol 2002; 138: 1137-9.
11. Dummer R, Urosevic M, Kempf W et al. Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. Dermatology 2003; 207: 116-18.
12. Miller R, Birmachu W,Gibson S et al. Cytokine induction by imiquimod: preclinical results and pharmacology. Chemiotherapie J 1994; 4: 148-9.
13. Wagner TL, Ahohen CL, Couture AM et al. Modulation of Th1 and Th2 cytokine production with the immune system modifiers R848 and imiquimod. Cell Immunol 1999; 191: 10-19.
14. Yagi H, Tokura Y, Furukawa F, Takigawa M. Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferon-gamma. J Invest Dermatol 1996; 107: 827-32.
15. French LE, Shapiro M, Junkins-Hopkins JM et al. Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy. J Am Acad Dermatol 2001; 45: 914-18.
16. Krathen RA, Ward S, Duvic M. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology 2003; 206: 142-7.